Vimta Labs Intrinsic Value
VIMTALABS • Healthcare
Current Stock Price
₹380.70
Primary Intrinsic Value
₹605.44
Market Cap
₹152.3 Cr
+100.0%
Upside
Median Value
₹761.40
Value Range
₹176 - ₹952
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
VIMTALABS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹605.44 | ₹484.35 - ₹726.53 | +59.0% | EPS: ₹27.52, Sector P/E: 22x |
| Book Value Method | asset | ₹951.75 | ₹856.58 - ₹1046.93 | +150.0% | Book Value/Share: ₹800.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹761.40 | ₹685.26 - ₹837.54 | +100.0% | Revenue/Share: ₹850.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹761.40 | ₹685.26 - ₹837.54 | +100.0% | EBITDA: ₹116.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹951.75 | ₹761.40 - ₹1142.10 | +150.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹176.13 | ₹158.52 - ₹193.74 | -53.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹425.18 | ₹382.66 - ₹467.70 | +11.7% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹761.40 | ₹685.26 - ₹837.54 | +100.0% | ROE: 18.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹703.82 | ₹633.44 - ₹774.20 | +84.9% | EPS: ₹27.52, BVPS: ₹800.00 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
VIMTALABS Intrinsic Value Analysis
What is the intrinsic value of VIMTALABS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Vimta Labs (VIMTALABS) is ₹761.40 (median value). With the current market price of ₹380.70, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹176.13 to ₹951.75, indicating ₹176.13 - ₹951.75.
Is VIMTALABS undervalued or overvalued?
Based on our multi-method analysis, Vimta Labs (VIMTALABS) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.08 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 18.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 33.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Vimta Labs
Additional stock information and data for VIMTALABS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2024 | ₹61 Cr | ₹23 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹88 Cr | ₹60 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹59 Cr | ₹40 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹37 Cr | ₹21 Cr | Positive Free Cash Flow | 8/10 |
| March 2020 | ₹24 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |